Ampio Pharm Stock Analysis
| AMPE Stock | USD 0.27 0.26 2,600% |
Ampio Pharm holds a debt-to-equity ratio of 0.038. Ampio Pharm's financial risk is the risk to Ampio Pharm stockholders that is caused by an increase in debt.
Asset vs Debt
Equity vs Debt
Ampio Pharm's liquidity is one of the most fundamental aspects of both its future profitability and its ability to meet different types of ongoing financial obligations. Ampio Pharm's cash, liquid assets, total liabilities, and shareholder equity can be utilized to evaluate how much leverage the Company is using to sustain its current operations. For traders, higher-leverage indicators usually imply a higher risk to shareholders. In addition, it helps Ampio Pink Sheet's retail investors understand whether an upcoming fall or rise in the market will negatively affect Ampio Pharm's stakeholders.
For many companies, including Ampio Pharm, marketable securities, inventories, and receivables are the most common assets that could be converted to cash. However, for Ampio Pharm, the most critical issue when managing liquidity is ensuring that current assets are properly aligned with current liabilities. If they are not, Ampio Pharm's management will need to obtain alternative financing to ensure there are always enough cash equivalents on the balance sheet to meet obligations.
Given that Ampio Pharm's debt-to-equity ratio measures a Company's obligations relative to the value of its net assets, it is usually used by traders to estimate the extent to which Ampio Pharm is acquiring new debt as a mechanism of leveraging its assets. A high debt-to-equity ratio is generally associated with increased risk, implying that it has been aggressive in financing its growth with debt. Another way to look at debt-to-equity ratios is to compare the overall debt load of Ampio Pharm to its assets or equity, showing how much of the company assets belong to shareholders vs. creditors. If shareholders own more assets, Ampio Pharm is said to be less leveraged. If creditors hold a majority of Ampio Pharm's assets, the Company is said to be highly leveraged.
Ampio Pharm is overvalued with Real Value of 0.2 and Hype Value of 0.27. The main objective of Ampio Pharm pink sheet analysis is to determine its intrinsic value, which is an estimate of what Ampio Pharm is worth, separate from its market price. There are two main types of Ampio Pharm's stock analysis: fundamental analysis and technical analysis.
The Ampio Pharm pink sheet is traded in the USA on PINK Exchange, with the market opening at 09:30:00 and closing at 16:00:00 every Mon,Tue,Wed,Thu,Fri except for officially observed holidays in the USA. Here, you can get updates on important government artifacts, including earning estimates, SEC corporate filings, announcements, and Ampio Pharm's ongoing operational relationships across important fundamental and technical indicators.
Ampio |
Ampio Pink Sheet Analysis Notes
The company has price-to-book (P/B) ratio of 0.21. Some equities with similar Price to Book (P/B) outperform the market in the long run. Ampio Pharm recorded a loss per share of 10.66. The entity had not issued any dividends in recent years. The firm had 1:20 split on the 12th of September 2023. Ampio Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development of immunomodulatory therapies for the treatment of pain from osteoarthritis in the United States. Its product pipeline includes AP-013, an intra-articular injection, which is in phase III clinical trial for the treatment of osteoarthritis of the knee AP-017, an intravenous ampion treatment that is in Phase II clinical trial to treat adult COVID-19 patients requiring oxygen supplementation AP-019, an Inhaled Ampion treatment, which is in Phase II clinical trial for the treatment of Adults with Respiratory Distress Due to COVID-19 and AP-018 that is in Phase I clinical trial to treat patients with prolonged respiratory symptoms due to COVID-19. Ampio Pharmaceuticals operates under Biotechnology classification in the United States and is traded on OTC Exchange. It employs 18 people.The quote for Ampio Pharm is published daily by the National Quotation Bureau and the company does not need to meet minimum requirements or file with the SEC. For more info on Ampio Pharm please contact Michael Martino at 720 437 6500 or go to https://ampiopharma.com.Ampio Pharm Investment Alerts
Many investors view ongoing market volatility as an opportunity to purchase more pink sheets at a favorable price or short it to generate a bearish trend profit opportunity. If you are one of those investors, make sure you clearly understand the position you are entering. Ampio Pharm's investment alerts are automatically generated signals that are significant enough to either complement your investing judgment regarding Ampio Pharm or challenge it. These alerts can help you understand what you are buying and avoid costly mistakes.
| Ampio Pharm is way too risky over 90 days horizon | |
| Ampio Pharm has some characteristics of a very speculative penny stock | |
| Ampio Pharm appears to be risky and price may revert if volatility continues | |
| Ampio Pharm has high likelihood to experience some financial distress in the next 2 years | |
| Net Loss for the year was (8.63 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| Ampio Pharm currently holds about 23.25 M in cash with (8.56 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.1. | |
| Latest headline from news.google.com: 270,284 traded Tengion volume spike 28 Jan 2026 liquidity is key - Meyka |
Ampio Market Capitalization
The company currently falls under 'Nano-Cap' category with a current market capitalization of 340.61 K. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Ampio Pharm's market, we take the total number of its shares issued and multiply it by Ampio Pharm's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and those looking for more risk prefer small-cap and mid-cap equities.Technical Drivers
As of the 25th of February, Ampio Pharm shows the Downside Deviation of 84.33, mean deviation of 679.65, and Risk Adjusted Performance of 0.2614. Ampio Pharm technical analysis gives you the methodology to make use of historical prices and volume patterns to determine a pattern that approximates the direction of the firm's future prices. Please confirm Ampio Pharm jensen alpha, as well as the relationship between the potential upside and skewness to decide if Ampio Pharm is priced correctly, providing market reflects its regular price of 0.27 per share. As Ampio Pharm appears to be a penny stock we also recommend to validate its total risk alpha numbers.Ampio Pharm Price Movement Analysis
The output start index for this execution was thirteen with a total number of output elements of fourty-eight. The Triangular Moving Average shows Ampio Pharm double smoothed mean price over a specified number of previous prices (i.e., averaged twice).
Ampio Pharm Insider Trading Activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Ampio Pharm insiders, such as employees or executives, is commonly permitted as long as it does not rely on Ampio Pharm's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Ampio Pharm insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Richard Giles over a year ago Acquisition by Richard Giles of 75000 shares of Ampio Pharm at 0.56 subject to Rule 16b-3 | ||
Michael Martino over a year ago Purchase by Michael Martino of 76890 shares of Ampio Pharm | ||
David Stevens over a year ago Purchase by David Stevens of 25000 shares of Ampio Pharm |
Ampio Pharm Outstanding Bonds
Ampio Pharm issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Ampio Pharm uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Ampio bonds can be classified according to their maturity, which is the date when Ampio Pharm has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
| MPLX LP 4125 Corp BondUS55336VAK61 | View | |
| AMPHENOL P NEW Corp BondUS032095AH42 | View | |
| US032095AJ08 Corp BondUS032095AJ08 | View | |
| APH 22 15 SEP 31 Corp BondUS032095AL53 | View | |
| US032095AP67 Corp BondUS032095AP67 | View |
Ampio Pharm Predictive Daily Indicators
Ampio Pharm intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of Ampio Pharm pink sheet daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.
Ampio Pharm Forecast Models
Ampio Pharm's time-series forecasting models are one of many Ampio Pharm's pink sheet analysis techniques aimed at predicting future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Ampio Pharm's historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.Ampio Pharm Debt to Cash Allocation
Many companies such as Ampio Pharm, eventually find out that there is only so much market out there to be conquered, and adding the next product or service is only half as profitable per unit as their current endeavors. Eventually, the company will reach a point where cash flows are strong, and extra cash is available but not fully utilized. In this case, the company may start buying back its stock from the public or issue more dividends.
Ampio Pharm currently holds 274 K in liabilities with Debt to Equity (D/E) ratio of 0.04, which may suggest the company is not taking enough advantage from borrowing. Ampio Pharm has a current ratio of 4.75, suggesting that it is liquid enough and is able to pay its financial obligations when due. Debt can assist Ampio Pharm until it has trouble settling it off, either with new capital or with free cash flow. So, Ampio Pharm's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Ampio Pharm sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Ampio to invest in growth at high rates of return. When we think about Ampio Pharm's use of debt, we should always consider it together with cash and equity.Ampio Pharm Assets Financed by Debt
Typically, companies with high debt-to-asset ratios are said to be highly leveraged. The higher the ratio, the greater risk will be associated with the Ampio Pharm's operation. In addition, a high debt-to-assets ratio may indicate a low borrowing capacity of Ampio Pharm, which in turn will lower the firm's financial flexibility.Ampio Pharm Corporate Bonds Issued
Most Ampio bonds can be classified according to their maturity, which is the date when Ampio Pharm has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
About Ampio Pink Sheet Analysis
Pink Sheet analysis is the technique used by a trader or investor to examine and evaluate how Ampio Pharm prices is reacting to, or reflecting on a current market direction and economic conditions. It can be used to make informed decisions about market timing, and when buying or selling Ampio shares will generate the highest return on investment. We also built our pink sheet analysis module to help investors to gain an insight into the world economy as a whole, the stock market, thematic ideas. a specific sector, or an individual Pink Sheet such as Ampio Pharm. By using and applying Ampio Pink Sheet analysis, traders can create a robust methodology for identifying Ampio entry and exit points for their positions.
Ampio Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development of immunomodulatory therapies for the treatment of pain from osteoarthritis in the United States. Its product pipeline includes AP-013, an intra-articular injection, which is in phase III clinical trial for the treatment of osteoarthritis of the knee AP-017, an intravenous ampion treatment that is in Phase II clinical trial to treat adult COVID-19 patients requiring oxygen supplementation AP-019, an Inhaled Ampion treatment, which is in Phase II clinical trial for the treatment of Adults with Respiratory Distress Due to COVID-19 and AP-018 that is in Phase I clinical trial to treat patients with prolonged respiratory symptoms due to COVID-19. Ampio Pharmaceuticals operates under Biotechnology classification in the United States and is traded on OTC Exchange. It employs 18 people.
Be your own money manager
As an investor, your ultimate goal is to build wealth. Optimizing your investment portfolio is an essential element in this goal. Using our pink sheet analysis tools, you can find out how much better you can do when adding Ampio Pharm to your portfolios without increasing risk or reducing expected return.Did you try this?
Run Performance Analysis Now
Performance AnalysisCheck effects of mean-variance optimization against your current asset allocation |
| All Next | Launch Module |
Complementary Tools for Ampio Pink Sheet analysis
When running Ampio Pharm's price analysis, check to measure Ampio Pharm's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Ampio Pharm is operating at the current time. Most of Ampio Pharm's value examination focuses on studying past and present price action to predict the probability of Ampio Pharm's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Ampio Pharm's price. Additionally, you may evaluate how the addition of Ampio Pharm to your portfolios can decrease your overall portfolio volatility.
| Financial Widgets Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets | |
| Content Syndication Quickly integrate customizable finance content to your own investment portal |